Merus to Present at the 2020 Wedbush PacGrow Healthcare Conference

UTRECHT, The Netherlands,and CAMBRIDGE, Mass., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics^® and Triclonics™), today announced that Bill Lundberg, M.D., President and Chief Executive Officer, will present a company overview at the 2020 Wedbush PacGrow Healthcare Conference on Wednesday, August 12, 2020 at 10:20 a.m. ET.

A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl. An archived presentation will be available on the Merus website for a limited time.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics^®. Multiclonics^® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, www.merus.nl and https://twitter.com/MerusNV.

You May Also Be Interested In

• AirBoss Announces Change of Auditor
• Hub Group, Inc. Securities Fraud Class Action Result of Erroneous Financial Statements and Approximately 31% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
• KBRA Assigns Preliminary Ratings to FMC GMSR Issuer Trust, Series 2026-GT1 (FMC GMSR 2026-GT1)